CURE vs IVV
Direxion Daily Healthcare Bull 3X ETF vs iShares Core S&P 500 ETF
Which is better, CURE or IVV?
Multi Alternative against Large Cap Blend.
IVV has a lower expense ratio. CURE led over 1Y and the full window, IVV over 3Y and 5Y. IVV is less concentrated, with 38.9% of the fund in its ten largest positions against 59.8%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | CURE | IVV |
|---|---|---|
| Expense Ratio | 0.93% | 0.03%Best |
| AUM | $164M | $896.5B |
| Dividend Yield | 0.98% | 1.10% |
| Holdings | 134 | 508 |
| YTD Return | +25.93%Best | +13.59% |
| 1Y Return | +60.78%Best | +17.54% |
| 3Y Return (annualized) | +16.35% | +22.46%Best |
| 5Y Return (annualized) | +6.86% | +13.28%Best |
| Volatility (annualized) | 41.8% | 14.3%Best |
| Max Drawdown | -69.2% | -33.9%Best |
| $10,000 over 5 years | $13,934 | $18,654Best |
| Top 10 Weight | 59.8% | 38.9%Best |
| Fund Family | Direxion Shares ETF Trust | iShares by BlackRock (US) |
| Category | Alternative | Equity |
| Style | Multi Alternative | Large Cap Blend |
| Inception | Jun 15, 2011 | May 15, 2000 |
Volatility and max drawdown are measured over the window both funds cover: Jun 15, 2011 to Oct 14, 2026 (15.3 years).
CURE vs IVV growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 15.3 years both funds cover.
CURE vs IVV Performance
Direxion Daily Healthcare Bull 3X ETF (CURE) is an ETF from Direxion Shares ETF Trust and iShares Core S&P 500 ETF (IVV) is an ETF from iShares by BlackRock (US). Over the past year CURE returned +60.78% while IVV returned +17.54%. Year to date, CURE is up 25.93% versus a gain of 13.59% for IVV.
Over three years, CURE compounded at +16.35% per year against +22.46% for IVV; over five years the annualized figures are +6.86% and +13.28% respectively. Across the full 15-year window we track, CURE has the edge at +24.84% annualized vs +13.06%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
CURE has been the more volatile fund, with annualized monthly volatility of 41.8% compared with 14.3% for IVV. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -69.2% for CURE and -33.9% for IVV. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.73. They usually move together, but the gap leaves some room for diversification.
Fees and Cost Over Time
CURE charges 0.93% per year while IVV charges 0.03%. On a $10,000 position that is $93 vs $3 annually, a gap of $90 per year that compounds over a long holding period. On income, CURE currently yields 0.98% against 1.10% for IVV.
Holdings Overlap
43.2% of CURE's money is in holdings IVV also owns. 0.6% of IVV's money is in holdings CURE also owns.
The two portfolios partly overlap.
7 positions in common, counted across the 49 positions we hold weights for in CURE and 506 in IVV, against full books of 134 and 508.
What only one of them owns
Our book lists 493 positions for IVV that do not appear in our book for CURE (98.8% of the fund), and 29 for CURE that do not appear in IVV (39.1%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in CURE | Weight in IVV | Difference |
|---|---|---|---|
| MRNAModerna Inc | 9.08% | 0.11% | 8.97% |
| VRTXNvaesrtex Pharmaceuticals Inc | 7.25% | 0.19% | 7.06% |
| REGNRegeneron Pharmaceuticals Common Stock Usd.001 | 6.78% | 0.11% | 6.67% |
| VEEVVeeva Systems | 6.54% | 0.06% | 6.48% |
| ILMNIllumina Inc. | 6.04% | 0.06% | 5.98% |
| DXCMDexcom Inc. | 5.27% | 0.05% | 5.22% |
| PODDInsulet Corporation | 2.25% | 0.01% | 2.24% |
43.2% of CURE is already inside IVV.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, CURE or IVV?
CURE has an expense ratio of 0.93% while IVV charges 0.03%. IVV is the cheaper option, by $90 a year on a $10,000 investment.
Which performed better, CURE or IVV?
Over the past year CURE returned +60.78% vs +17.54% for IVV, so CURE leads on 1-year performance. Over the longest common window we track (15 years), CURE annualized +24.84% vs +13.06% for IVV. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, CURE or IVV?
CURE has been the more volatile fund at 41.8% annualized versus 14.3% for IVV. Worst drawdown: CURE -69.2% vs IVV -33.9%.
Should I hold both CURE and IVV?
CURE and IVV have a monthly-return correlation of 0.73, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between CURE and IVV?
43.2% of CURE's money is in holdings IVV also owns. 0.6% of IVV's is in holdings CURE also owns. They hold 7 positions in common, counted across the 49 positions we hold weights for in CURE and 506 in IVV.
Which pays a higher dividend, CURE or IVV?
CURE yields 0.98% while IVV yields 1.10%, so IVV currently pays the higher dividend yield.
Is IVV better than CURE?
IVV has a lower expense ratio. CURE led over 1Y and the full window, IVV over 3Y and 5Y. IVV is less concentrated, with 38.9% of the fund in its ten largest positions against 59.8%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.